Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: A subgroup analysis from the HOVON-65/GMMG-HD4 trial

Haematologica

Volumn 99, Issue 1, 2014, Pages 148-154

  Scheid, Christof ^a   Sonneveld, Pieter ^b   Schmidt Wolf, Ingo G H ^b   Van Der Holt, Bronno ^b   El Jarari, Laila ^b   Bertsch, Uta ^c   Salwender, Hans ^b   Zweegman, Sonja ^b   Blau, Igor Wolfgang ^b   Vellenga, Edo ^b   Weisel, Katja ^b   Pfreundschuh, Michael ^b   Jie, Kon Siong ^b   Neben, Kai ^c   Van De Velde, Helgi ^d   Duehrsen, Ulrich ^b   Schaafsma, M Ron ^b   Lindemann, Walter ^b   Kersten, Marie José ^b   Peter, Norma ^b   Hänel, Mathias ^b   Croockewit, Sandra ^b   Martin, Hans ^b   Wittebol, Shulamiet ^b   Bos, Gerard Mj ^b   Van Marwijk Kooy, Marinus ^b   Wijermans, Pierre ^b   Goldschmidt, Hartmut ^c   Lokhorst, Henk M ^b   more..

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b HOVON ^*  (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CREATININE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; REMISSION INDUCTION; RENAL INSUFFICIENCY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84892620823     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.087585     Document Type: Article

References (30)

1. Dimopoulos MA, Terpos E. Renal insufficiency and failure. Hematology Am Soc Hematol Educ Program. 2010:431-6.
2. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994;53(4):207-12.
3. Salmon SE, Durie BG. Cellular kinetics in multiple myeloma. A new approach to staging and treatment. Arch Intern Med. 1975;135(1):131-8.
4. Greipp PR, San Miguel J, Durie BGM, Crowley J, Barlogie B, Blade J, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;23(15):3412-20.
5. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Cancer. 2005;103(6): 1195-200.
6. San-Miguel J F, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008;22(4): 842-9.
7. Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F, et al. Light chain-induced acute renal failure can be reversed by borte-zomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010;28(30):4635-41.
8. Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, et al. VMP (bortezomib, melphalan, and pred-nisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol. 2009;27(36):6086-93.
9. Eleftherakis-Papapiakovou E, Kastritis E, Roussou M, Gkotzamanidou M, Grapsa I, Psimenou E, et al. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leuk Lymphoma. 2011;52(12): 2299-303.
10. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El-Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 2012;30 (24):2946-55.
11. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28(33): 4976-84.
12. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129(6):755-62.
13. Mateos M-V, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259-66.
14. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melpha-lan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370 (9594):1209-18.
15. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexam-ethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28(30):4621-9.
16. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114(4):822-9.
17. San Miguel J F, Lahuerta JJ, Garcia-Sanz R, Alegre A, Blade J, Martinez R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J. 2000;1(1):28-36.
18. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15(7):812-6.
19. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol. 2006;134(4):385-90.
20. Carlson K. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant. 2005; 35(10):985-90.
21. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005;75(1):27-33.
22. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19): 1782-91.
23. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-81.
24. Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940-8.
25. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26(2): 349-55.
26. Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27(2):423-9.
27. Chanan-Khan AA, San Miguel JF, Jagannath S, Ludwig H, Dimopoulos MA. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res. 2012;18(8): 2145-63.
28. Gaballa MR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, et al. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012;5(1):51-66; quiz 7-8.
29. Costa LJ, Abbas J, Ortiz-Cruz KL, Kang Y, Stuart RK. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. Eur J Haematol. 2012;89(5):432-4.
30. Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, et al. Safety and efficacy of bortezomib-melphalan-pred-nisone-thalidomide followed by borte-zomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-pred-nisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood. 2011;118 (22):5759-66.